Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.



Giuseppe Scozzafava

Research Scientist / Lab Manager

Functional Genomics of Ankylosing Spondylitis

Giuseppe joined the Knight group (Genomics of Immunity, Wellcome Centre for Human Genetics) in 2015 as a researcher / project manager for the Arthritis UK (now Versus Arthritis) sponsored ankylosing spondylitis research project. Ankylosing spondylitis (AS) is highly heritable with over 40 disease-associated loci on recent genome-wide association studies (GWAS). In most cases, association involves regulatory DNA variants and the specific modulated gene(s), pathways and mechanism of action remain unresolved, limiting translational utility. The goal of this research is to determine the functional basis for genetic associations with AS to advance understanding of disease pathogenesis and define opportunities for therapeutic intervention. 

Giuseppe graduated "110/110 con lode" (BSc 1st Hons equivalent) in Biological Sciences from “La Sapienza” University of Rome. He held several positions in the biotech industry, working in Quality Control, Research & Development and Customer Support Services at Amersham Biosciences (now GE Healthcare), contributing to the development of technologies and products used in genomics and proteomics research. In 2004 he joined a small research group at the Wellcome Trust Centre for Human Genetics, University of Oxford focusing on the development of a next generation sequencing scheme based on cyclic ligation. Between 2012 and 2015 he was part of the Screening and Assay Development group at the Structural Genomics Consortium, University of Oxford where he worked on screening inhibitors for human histone demethylases.